Immuneering Corp (IMRX) IPO Opens 30% Higher

Today's IPO for Immuneering Corporation (Nasdaq: IMRX) opened for trading at $19.50 after pricing 7,500,000 shares of Class A common stock at a public offering price of $15.00 per share. The company had planned to offer 7,000,000 shares at $14-$16 per share.

Morgan Stanley, Jefferies, Cowen and Guggenheim Securities are acting as joint book-running managers.

Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Immuneering has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, Immuneering has developed a disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its wholly owned pipeline. Immuneering’s current development programs in oncology are focused on providing potential treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Immuneering’s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Additionally, Immuneering has six other oncology programs in the discovery stage that are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage.

You May Also Be Interested In

• Absci prices $100M stock offering with Eli Lilly among investors
• Jefferies Financial Group (JEF) Misses Q2 EPS by 22c
• SK hynix files for Nasdaq IPO under ticker symbol SKHY